US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
EP3276000A3
(en)
*
|
2012-05-25 |
2018-02-21 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
EP3763810A3
(en)
*
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
CN110423282B
(zh)
|
2013-02-15 |
2023-09-08 |
加利福尼亚大学董事会 |
嵌合抗原受体及其使用方法
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
CN105209065B
(zh)
*
|
2013-03-14 |
2020-07-31 |
贝里坤制药股份有限公司 |
控制t细胞增殖的方法
|
JP6005572B2
(ja)
*
|
2013-03-28 |
2016-10-12 |
Kddi株式会社 |
動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、およびプログラム
|
CA3185368A1
(en)
|
2013-04-03 |
2014-10-09 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted t cells derived from pluripotent stem cells
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
ES2645393T3
(es)
|
2013-05-29 |
2017-12-05 |
Cellectis |
Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
PT3066201T
(pt)
|
2013-11-07 |
2018-06-04 |
Massachusetts Inst Technology |
Métodos e composições relacionadas com crispr com arng reguladores
|
EP3071687B1
(en)
*
|
2013-11-22 |
2019-07-31 |
Cellectis |
Method of engineering chemotherapy drug resistant t-cells for immunotherapy
|
US10357515B2
(en)
*
|
2013-11-22 |
2019-07-23 |
Cellectis |
Method for generating batches of allogeneic T-cells with averaged potency
|
RU2689558C1
(ru)
*
|
2013-11-22 |
2019-05-28 |
Селлектис |
Способ конструирования аллогенных и устойчивых к лекарственным препаратам т-клеток для иммунотерапии
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
EP3083691A2
(en)
*
|
2013-12-20 |
2016-10-26 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
NZ721908A
(en)
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
US10526406B2
(en)
|
2014-01-14 |
2020-01-07 |
Cellectis |
Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
|
CN111705365A
(zh)
|
2014-02-11 |
2020-09-25 |
科罗拉多州立大学董事会(法人团体) |
Crispr支持的多路基因组工程化
|
CN106132423B
(zh)
|
2014-02-14 |
2020-07-31 |
贝里坤制药股份有限公司 |
用诱导型嵌合多肽活化t细胞的方法
|
RU2753965C2
(ru)
*
|
2014-02-14 |
2021-08-24 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Химерные антигенные рецепторы и способы их получения
|
CN106029875A
(zh)
|
2014-02-14 |
2016-10-12 |
塞勒克提斯公司 |
为了靶向存在于免疫细胞和病理细胞两者上的抗原而工程化的免疫治疗细胞
|
AU2015220762B2
(en)
*
|
2014-02-21 |
2019-05-02 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
US11885807B2
(en)
|
2014-03-05 |
2024-01-30 |
Autolus Limited |
Method for depleting malignant T-cells
|
JP6767872B2
(ja)
*
|
2014-03-05 |
2020-10-14 |
ユーシーエル ビジネス リミテッド |
T細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体(car)
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
EP3116902B1
(en)
|
2014-03-11 |
2020-01-01 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
US9944709B2
(en)
|
2014-03-19 |
2018-04-17 |
Cellectis |
CD123 specific chimeric antigen receptors for cancer immunotherapy
|
CN106795221B
(zh)
|
2014-04-03 |
2022-06-07 |
塞勒克提斯公司 |
用于癌症免疫治疗的cd33特异性嵌合抗原受体
|
WO2015155341A1
(en)
*
|
2014-04-11 |
2015-10-15 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
KR102595473B1
(ko)
*
|
2014-04-18 |
2023-10-30 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
|
EP3137498A1
(en)
|
2014-05-02 |
2017-03-08 |
Cellectis |
Cs1 specific multi-chain chimeric antigen receptor
|
EP3169773B1
(en)
|
2014-07-15 |
2023-07-12 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
EA034081B1
(ru)
|
2014-07-29 |
2019-12-25 |
Селлектис |
Ror1-(ntrkr1)-специфические химерные антигенные рецепторы для иммунотерапии рака
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
EP3194432B1
(en)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
US10800830B2
(en)
|
2014-08-08 |
2020-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
WO2016034666A1
(en)
|
2014-09-04 |
2016-03-10 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
AU2015334847A1
(en)
*
|
2014-10-24 |
2017-06-08 |
Bcrt Holding Bv |
T cell-based immunotherapeutics
|
CA2964948A1
(en)
*
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
GB201421096D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
CA2973525C
(en)
|
2015-01-26 |
2021-12-14 |
Cellectis |
Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
US10557140B2
(en)
*
|
2015-02-02 |
2020-02-11 |
Industry-Academic Cooperation Foundation, Dankook University |
CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof
|
AU2016214301B2
(en)
*
|
2015-02-06 |
2022-05-19 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
CN108064283B
(zh)
|
2015-02-24 |
2024-01-09 |
加利福尼亚大学董事会 |
结合触发的转录开关及其使用方法
|
CN107073138B
(zh)
*
|
2015-03-02 |
2018-06-29 |
上海斯丹赛生物技术有限公司 |
降低由pd-l1诱导的免疫耐受性
|
AU2016231061B2
(en)
*
|
2015-03-11 |
2020-11-26 |
Cellectis |
Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
|
AU2016235388B2
(en)
*
|
2015-03-20 |
2022-02-03 |
Children's National Medical Center |
Generating virus or other antigen-specific T cells from a naive T cell population
|
GB201504840D0
(en)
*
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
WO2016166268A1
(en)
|
2015-04-17 |
2016-10-20 |
Cellectis |
Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
WO2016179319A1
(en)
*
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
IL255697B2
(en)
|
2015-05-18 |
2023-11-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR programming using fusion proteins
|
WO2016187508A2
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute Inc. |
Shared neoantigens
|
US10752670B2
(en)
|
2015-05-20 |
2020-08-25 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
|
US20170014449A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Elwha LLC, a limited liability company of the State of Delaware |
Site-specific epigenetic editing
|
JP6954890B2
(ja)
*
|
2015-07-13 |
2021-10-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
CN108472314A
(zh)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
修饰的细胞和治疗方法
|
KR20180041152A
(ko)
|
2015-08-11 |
2018-04-23 |
셀렉티스 |
Cd38 항원 타겟팅 및 cd38 유전자 불활성화를 위하여 조작된 면역치료용 세포들
|
WO2017040195A1
(en)
*
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
WO2017040324A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
MX2018004146A
(es)
*
|
2015-10-05 |
2018-11-09 |
Prec Biosciences Inc |
Células modificadas genéticamente que comprenden un gen mano modificado de la región constante alfa del receptor de células t.
|
US10799535B2
(en)
|
2015-10-05 |
2020-10-13 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017070429A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
JP7067793B2
(ja)
|
2015-10-23 |
2022-05-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸塩基編集因子およびその使用
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
JP7092662B2
(ja)
|
2015-10-30 |
2022-06-28 |
チルドレンズ ナショナル メディカル センター |
ナイーブt細胞集団からのhpv抗原特異的t細胞の生成
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
WO2017079673A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
EP3370514A4
(en)
*
|
2015-11-05 |
2019-03-27 |
Baylor College of Medicine |
EFFICIENT SCALABLE XENOTRANAPLANT SYSTEM FROM ONE PATIENT BASED ON A CHICKEN CHORIOAL ANTI-TEMEMBRBRANE (CAM) IN VIVO MODEL
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
EP3389677A4
(en)
*
|
2015-12-18 |
2019-05-22 |
Sangamo Therapeutics, Inc. |
TARGETED DESTRUCTION OF THE T-CELL RECEPTOR
|
CN105505869A
(zh)
*
|
2015-12-21 |
2016-04-20 |
河南大学淮河医院 |
一种针对肿瘤干细胞的嵌合抗原受体t细胞
|
EP3184548A1
(en)
*
|
2015-12-23 |
2017-06-28 |
Miltenyi Biotec GmbH |
Chimeric antigen receptor with cytokine receptor activating or blocking domain
|
BR112018013914A2
(pt)
|
2016-01-08 |
2018-12-11 |
Univ California |
polipeptídeos heterodiméricos condicionalmente ativos e métodos de utilização deste
|
GB201604213D0
(en)
*
|
2016-03-11 |
2016-04-27 |
Proximagen Ltd |
Drug combination and its use in therapy
|
KR20220047898A
(ko)
*
|
2016-03-11 |
2022-04-19 |
2세븐티 바이오, 인코포레이티드 |
게놈 편집 면역 효과기 세포
|
CN109415687A
(zh)
*
|
2016-04-07 |
2019-03-01 |
蓝鸟生物公司 |
嵌合抗原受体t细胞组合物
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
BR112018070676A2
(pt)
*
|
2016-04-15 |
2019-02-05 |
Zymeworks Inc |
construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
|
US10894093B2
(en)
|
2016-04-15 |
2021-01-19 |
Cellectis |
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
EP3429634A1
(en)
|
2016-04-15 |
2019-01-23 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
JP7058223B2
(ja)
|
2016-04-15 |
2022-04-21 |
メモリアル スローン ケタリング キャンサー センター |
トランスジェニックt細胞及びキメラ抗原受容体t細胞組成物及び関連方法
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
US10017760B2
(en)
|
2016-06-24 |
2018-07-10 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
CA3029761A1
(en)
|
2016-07-06 |
2018-01-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
BR112019003100A2
(pt)
|
2016-08-24 |
2019-07-09 |
Sangamo Therapeutics Inc |
regulação da expressão gênica usando nucleases manipuladas
|
WO2018039448A1
(en)
*
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
EP4282969A3
(en)
*
|
2016-09-02 |
2024-01-31 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
WO2018052828A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Biotech, Inc. |
Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
|
JP2019536437A
(ja)
|
2016-10-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Hpv特異的結合分子
|
CA3038690A1
(en)
|
2016-10-05 |
2018-04-12 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
US11591582B2
(en)
*
|
2016-10-11 |
2023-02-28 |
2Seventy Bio, Inc. |
TCRα homing endonuclease variants
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
AU2017347637B2
(en)
*
|
2016-10-19 |
2024-02-15 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
EP3529347A1
(en)
|
2016-10-19 |
2019-08-28 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
DK3321280T3
(da)
|
2016-11-10 |
2021-02-22 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Immunmodulatorer til reduktion af immunresistens i et melanom og andre proliferative sygdomme
|
US20190263906A1
(en)
|
2016-11-10 |
2019-08-29 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
|
WO2018098365A2
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
WO2018115189A1
(en)
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
EP3558368A4
(en)
|
2016-12-23 |
2020-12-30 |
MacroGenics, Inc. |
ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
AU2018208614A1
(en)
*
|
2017-01-10 |
2019-07-11 |
The General Hospital Corporation |
Modified T cells and methods of their use
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
AU2018219226A1
(en)
|
2017-02-07 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
EP4317447A3
(en)
*
|
2017-02-15 |
2024-05-01 |
2seventy bio, Inc. |
Donor repair templates multiplex genome editing
|
CN110582288A
(zh)
|
2017-02-28 |
2019-12-17 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
EP3592777A1
(en)
|
2017-03-10 |
2020-01-15 |
President and Fellows of Harvard College |
Cytosine to guanine base editor
|
EP3595705A1
(en)
|
2017-03-15 |
2020-01-22 |
Oxford BioMedica (UK) Limited |
Method
|
AU2018237159A1
(en)
|
2017-03-22 |
2019-09-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
KR20190130613A
(ko)
|
2017-03-23 |
2019-11-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
BR112019020203A2
(pt)
|
2017-03-31 |
2020-06-02 |
Cellectis Sa |
Células imunes universais modificadas do receptor de anticorpos quiméricos anti-cd22
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
AU2018251150B2
(en)
|
2017-04-13 |
2024-05-09 |
Albert-Ludwigs-Universität Freiburg |
New sequence specific reagents targeting CCR5 in primary hematopoietic cells
|
CA3060443A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
DK3391907T3
(da)
|
2017-04-20 |
2020-03-09 |
Iomx Therapeutics Ag |
Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
EP3621981A2
(en)
*
|
2017-05-12 |
2020-03-18 |
CRISPR Therapeutics AG |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
MA49403A
(fr)
|
2017-06-12 |
2021-03-24 |
Obsidian Therapeutics Inc |
Compositions de pde5 et méthodes d'immunothérapie
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
US20210139870A1
(en)
|
2017-06-19 |
2021-05-13 |
Cellectis |
Anti-hbv combination therapies involving specific endonucleases
|
EP3538645B1
(en)
|
2017-06-20 |
2021-01-20 |
Institut Curie |
Immune cells defective for suv39h1
|
AU2018288863A1
(en)
*
|
2017-06-22 |
2020-01-30 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US11053484B2
(en)
|
2017-06-30 |
2021-07-06 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
EP3645036A1
(en)
|
2017-06-30 |
2020-05-06 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
EP3640333A4
(en)
|
2017-07-14 |
2020-12-30 |
Cure Genetics Co., Ltd |
GENE EDITING SYSTEM AND GENE EDITING METHOD
|
MX2020000595A
(es)
|
2017-07-17 |
2020-09-10 |
Janssen Biotech Inc |
Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso.
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
EP3638260A1
(en)
|
2017-07-21 |
2020-04-22 |
Cellectis |
Engineered immune cells resistant to tumor microoenvironment
|
AU2018306307A1
(en)
*
|
2017-07-25 |
2020-02-20 |
Board Of Regents, The University Of Texas System |
Enhanced chimeric antigen receptors and use thereof
|
WO2019020733A1
(en)
|
2017-07-26 |
2019-01-31 |
Cellectis |
METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
US20200230221A1
(en)
|
2017-09-19 |
2020-07-23 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
US11618896B2
(en)
|
2017-09-21 |
2023-04-04 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
CN111954679A
(zh)
|
2017-10-03 |
2020-11-17 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
USES OF BASIC EDITORS ADENOSINE
|
CA3084476A1
(en)
|
2017-10-19 |
2019-04-25 |
Cellectis |
Targeted gene integration of nk inhibitors genes for improved immune cells therapy
|
KR20200094147A
(ko)
|
2017-10-31 |
2020-08-06 |
알로젠 테라퓨틱스 인코포레이티드 |
동종이계 키메라 항원 수용체 t 세포를 투여하기 위한 방법 및 조성물
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
KR20200100060A
(ko)
|
2017-11-17 |
2020-08-25 |
이오반스 바이오테라퓨틱스, 인크. |
미세 바늘 흡인물 및 소형 생검물로부터의 til 확장
|
WO2019106163A1
(en)
|
2017-12-01 |
2019-06-06 |
Cellectis |
Reprogramming of genetically engineered primary immune cells
|
KR102439221B1
(ko)
|
2017-12-14 |
2022-09-01 |
프로디자인 소닉스, 인크. |
음향 트랜스듀서 구동기 및 제어기
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
US20190194617A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
IL309585A
(en)
|
2017-12-22 |
2024-02-01 |
Fate Therapeutics Inc |
Enhanced effector training cells and their use
|
WO2019119822A1
(en)
*
|
2017-12-23 |
2019-06-27 |
Uwell Biopharma Inc. |
Pharmaceutical chimeric receptor composition and method thereof
|
CA3086267A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Method for improving production of car t cells
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
JP2021509586A
(ja)
|
2018-01-08 |
2021-04-01 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍抗原特異的t細胞について濃縮されたtil製品を生成するためのプロセス
|
US11779602B2
(en)
|
2018-01-22 |
2023-10-10 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
WO2019149743A1
(en)
|
2018-01-30 |
2019-08-08 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
GB201801920D0
(en)
*
|
2018-02-06 |
2018-03-21 |
Autolus Ltd |
Polypeptides and methods
|
AU2019216982A1
(en)
*
|
2018-02-11 |
2020-08-27 |
Memorial Sloan-Kettering Cancer Center |
Non-HLA restricted T cell receptors and uses thereof
|
CA3093449A1
(en)
*
|
2018-03-09 |
2019-09-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2019178518A1
(en)
*
|
2018-03-16 |
2019-09-19 |
The Regents Of The University Of California |
Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
|
JP2021519061A
(ja)
|
2018-03-29 |
2021-08-10 |
フェイト セラピューティクス,インコーポレイテッド |
操作された免疫エフェクター細胞およびその使用
|
JP2021520202A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
JP2021520211A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現するt細胞、関連ポリヌクレオチド、および方法
|
PE20201345A1
(es)
|
2018-04-05 |
2020-11-25 |
Juno Therapeutics Inc |
Receptores de celulas t, y celulas disenadas que expresan los mismos
|
WO2019200122A1
(en)
|
2018-04-12 |
2019-10-17 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
CA3098303A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US20210268028A1
(en)
|
2018-07-02 |
2021-09-02 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
EP4324851A3
(en)
|
2018-07-19 |
2024-05-15 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with bcma specificity and uses thereof
|
US20220177524A1
(en)
*
|
2018-07-26 |
2022-06-09 |
Nanjing Legend Biotech Co., Ltd. |
Nef-containing t cells and methods of producing thereof
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
CN112771071A
(zh)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
胶原蛋白定位的免疫调节分子及其方法
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
BR112021008573A2
(pt)
|
2018-11-05 |
2021-10-26 |
Iovance Biotherapeutics, Inc. |
Métodos para expandir linfócitos infiltrantes de tumor em uma população terapêutica de linfócitos infiltrantes de tumor, para tratar um sujeito com câncer e de expansão de células t, população terapêutica de linfócitos infiltrantes de tumor, composição de linfócitos infiltrantes de tumor, saco de infusão estéril, preparação criopreservada, e, uso da composição de linfócitos infiltrantes de tumor.
|
CN113272420A
(zh)
|
2018-11-05 |
2021-08-17 |
艾欧凡斯生物治疗公司 |
经改进的肿瘤反应性t细胞的选择
|
SG11202104663PA
(en)
|
2018-11-05 |
2021-06-29 |
Iovance Biotherapeutics Inc |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
US20220031749A1
(en)
|
2018-11-28 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
BR112021010248A2
(pt)
|
2018-11-29 |
2021-08-17 |
Board Of Regents, The University Of Texas System |
métodos para expansão ex vivo de células naturais killer e uso dos mesmos
|
EP3887507A1
(en)
|
2018-11-30 |
2021-10-06 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
JP2022514023A
(ja)
|
2018-12-19 |
2022-02-09 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
JP2022522473A
(ja)
|
2019-03-01 |
2022-04-19 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
EP3942040A1
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
KR20210148293A
(ko)
|
2019-04-03 |
2021-12-07 |
프리시젼 바이오사이언시스 인코포레이티드 |
마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
|
TW202106704A
(zh)
*
|
2019-04-26 |
2021-02-16 |
美商艾洛基因醫療公司 |
抗利妥昔單抗嵌合抗原受體及其用途
|
EA202192975A1
(ru)
|
2019-04-30 |
2022-02-01 |
Криспр Терапьютикс Аг |
Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
EP3736330A1
(en)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Modified adeno-associated virus (aav) particles for gene therapy
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
AU2020286493A1
(en)
*
|
2019-06-01 |
2022-01-27 |
Sivec Biotechnologies, Llc |
A bacterial platform for delivery of gene-editing systems to eukaryotic cells
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
US20220372138A1
(en)
|
2019-07-05 |
2022-11-24 |
Iomx Therapeutics Ag |
Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
|
WO2021013950A1
(en)
|
2019-07-23 |
2021-01-28 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
WO2021016585A1
(en)
|
2019-07-24 |
2021-01-28 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
EP4017526A1
(en)
*
|
2019-08-20 |
2022-06-29 |
Precision BioSciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
EP4021937A1
(en)
|
2019-08-27 |
2022-07-06 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
EP4025686A4
(en)
|
2019-09-03 |
2023-09-13 |
Myeloid Therapeutics, Inc. |
GENOMIC INTEGRATION METHODS AND COMPOSITIONS
|
CA3150224A1
(en)
|
2019-09-10 |
2021-03-18 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US20240139242A1
(en)
|
2019-10-18 |
2024-05-02 |
Trustees Of Boston University |
Cal-t constructs and uses thereof
|
WO2021081378A1
(en)
|
2019-10-25 |
2021-04-29 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
TW202134429A
(zh)
*
|
2019-11-25 |
2021-09-16 |
國立大學法人京都大學 |
T細胞主細胞庫
|
JP2023504081A
(ja)
*
|
2019-11-27 |
2023-02-01 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
神経膠芽細胞腫及び他の癌を処置するためのナチュラルキラー細胞免疫療法
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
US20230220341A1
(en)
|
2019-12-11 |
2023-07-13 |
lovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
US20230068949A1
(en)
|
2019-12-23 |
2023-03-02 |
Cellectis |
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
IL294388A
(en)
|
2020-01-14 |
2022-08-01 |
Synthekine Inc |
il2 orthologs and methods of use
|
CA3167065A1
(en)
|
2020-02-24 |
2021-09-02 |
Regina Junhui LIN |
Bcma car-t cells with enhanced activities
|
IL295966A
(en)
|
2020-03-03 |
2022-10-01 |
Janssen Biotech Inc |
Gamma delta t cells and their uses
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
IL296241A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Compositions and methods for immunotherapy for npm1c-positive cancer
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
US20230212613A1
(en)
|
2020-05-06 |
2023-07-06 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
EP3910331A1
(en)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
|
US20230228739A1
(en)
|
2020-07-03 |
2023-07-20 |
Cellectis S.A. |
Method for determining potency of chimeric antigen receptor expressing immune cells
|
WO2022008027A1
(en)
|
2020-07-06 |
2022-01-13 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
JP2023535371A
(ja)
|
2020-07-17 |
2023-08-17 |
シミュレックス インコーポレイテッド |
免疫抑制シグナル伝達をリダイレクトするためのキメラMyD88受容体ならびに関連する組成物および方法
|
EP4185616A1
(en)
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
AU2021316727A1
(en)
|
2020-07-30 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immune cells defective for SOCS1
|
WO2022023529A1
(en)
|
2020-07-31 |
2022-02-03 |
Cellectis S.A. |
Dual car-t cells
|
US20220031751A1
(en)
|
2020-08-03 |
2022-02-03 |
Kyverna Therapeutics, Inc. |
Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
|
WO2022036224A1
(en)
|
2020-08-14 |
2022-02-17 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Chimeric antigen receptor t cells for treating autoimmunity
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
AU2021376354A1
(en)
|
2020-11-04 |
2023-06-22 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
WO2022101363A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
WO2022109277A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Pact Pharma, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
|
EP4251645A1
(en)
|
2020-11-25 |
2023-10-04 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
EP4251746A1
(en)
|
2020-11-30 |
2023-10-04 |
Cellectis SA |
Use of aminoquinoline compounds for higher gene integration
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
WO2022135457A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
广东菲鹏制药股份有限公司 |
一种抗pd-l1抗体及其应用
|
JP2024502094A
(ja)
|
2020-12-30 |
2024-01-17 |
アラウノス セラピューティクス インコーポレイテッド |
多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
|
JP2024506557A
(ja)
|
2021-01-29 |
2024-02-14 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
CA3212439A1
(en)
|
2021-03-19 |
2022-09-22 |
Michelle SIMPSON-ABELSON |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
CA3216563A1
(en)
|
2021-04-30 |
2022-11-03 |
Beatriz Aranda-Orgilles |
New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
|
WO2022235662A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Pd-1遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
AU2022277649A1
(en)
|
2021-05-21 |
2023-11-30 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
KR20240021826A
(ko)
|
2021-06-15 |
2024-02-19 |
알로젠 테라퓨틱스 인코포레이티드 |
동종이계 car t 세포 지속성을 연장시키기 위한 숙주 cd70+ 동종반응성 세포의 선택적 표적화
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
WO2023007431A1
(en)
|
2021-07-29 |
2023-02-02 |
Takeda Pharmaceutical Company Limited |
Engineered immune cell that specifically targets mesothelin and uses thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
AU2022343729A1
(en)
|
2021-09-09 |
2024-03-21 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
AU2022395500A1
(en)
|
2021-11-23 |
2024-05-23 |
Cellectis Sa |
New tale protein scaffolds with improved on-target/off-target activity ratios
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023133509A2
(en)
*
|
2022-01-08 |
2023-07-13 |
Carogen Corporation |
Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023233003A1
(en)
|
2022-06-03 |
2023-12-07 |
Cellectis Sa |
Tale base editors for gene and cell therapy
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024022509A1
(en)
*
|
2022-07-29 |
2024-02-01 |
Nanjing Legend Biotech Co., Ltd. |
Methods for promoting persistence of cell therapy
|
WO2024055018A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
WO2024055017A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
CN116284370B
(zh)
*
|
2023-02-27 |
2024-05-28 |
南京立顶医疗科技有限公司 |
一种多聚体糖化血红蛋白单克隆抗体及制备方法
|
CN116987699A
(zh)
*
|
2023-09-05 |
2023-11-03 |
深圳市艾迪贝克生物医药有限公司 |
用于制备通用型car-t细胞的基因片段、其工具系统及应用
|
CN117164714B
(zh)
*
|
2023-10-08 |
2024-04-23 |
北京奇迈永华生物科技有限公司 |
一种靶向bcma的抗体及其应用
|